In our study, we found that a low expression of Mfn2 was related to cisplatin resistance in lung adenocarcinoma cells, and the expression of Mfn2 in A549/DDP cells was significantly increased following co-treatment with cisplatin and SMI, followed by reduced mitochondrial fragmentation. This evidence concerns the gene MFN2 and lung adenocarcinoma.